Loading market dashboard
Taysha Gene Therapies, Inc.
TSHAHealthcareNASDAQUS
Loading analysis workspace
Estimates, scoring, valuation assumptions, and peer comparison in one research surface.
Taysha Gene Therapies, Inc. · Forecast overview
Bars show expected revenue while the line tracks expected EPS.
| Period | Revenue avg | Revenue range | EBITDA | EPS avg | Analysts |
|---|---|---|---|---|---|
| Dec 2030 | $957.88M | $957.88M - $957.88M | -$574.73M | $1.00 | 3 |
| Dec 2029 | $479.49M | $479.49M - $479.49M | -$287.69M | $0.228 | 5 |
| Dec 2028 | $150.22M | $149.09M - $151.34M | -$90.13M | -$0.259 | 6 |
| Dec 2027 | $38.90M | $38.90M - $38.90M | -$23.34M | -$0.32 | 7 |
| Dec 2026 | $2.00M | $2.00M - $2.00M | -$1.20M | -$0.475 | 9 |
| Dec 2025 | $5.87M | $4.26M - $9.72M | -$3.52M | -$0.36 | 8 |
| Dec 2024 | $8.25M | $8.14M - $8.45M | -$4.95M | -$0.37 | 7 |
| Dec 2023 | $14.16M | $14.16M - $14.16M | -$8.49M | -$0.746 | 6 |
| Dec 2022 | $8.18M | $6.97M - $12.77M | -$1.64M | -$2.944 | 2 |